meningococcus

(redirected from Neisseria meningitidis)
Also found in: Dictionary, Medical, Acronyms, Wikipedia.
Related to Neisseria meningitidis: Neisseria gonorrhoeae

Meningococcus

A major human pathogen belonging to the bacterial genus Neisseria, and the cause of meningococcal meningitis and meningococcemia. The official designation is N. meningitidis. The meningococcus is a gram-negative, aerobic, nonmotile diplococcus. It is fastidious in its growth requirements and is very susceptible to adverse physical and chemical conditions.

Humans are the only known natural host of the meningococcus. Transmission occurs by droplets directly from person to person. Fomites and aerosols are probably unimportant in the spread of the organism. The most frequent form of host-parasite relationship is asymptomatic carriage in the nasopharynx.

The most common clinical syndrome caused by the meningococcus is meningitis, which is characterized by fever, headache, nausea, vomiting, and neck stiffness and has a fatality rate of 15% (higher in infants and adults over 60). Disturbance of the state of consciousness quickly occurs, leading to stupor and coma. Many cases also have a typical skin rash consisting of petechiae or purpura. See Meningitis

meningococcus

[mə¦niŋ·gə¦käk·əs]
(microbiology)
Common name for Neisseria meningitidis.
References in periodicals archive ?
2012) Advances with vaccination against Neisseria meningitidis.
Orren A, Owen EP, Henderson HE, et al Complete deficiency of the sixth complement component (C6Q0), susceptibility to Neisseria meningitidis infections, and analysis of the frequencies of C6Q0 gene defects in South Africans.
Under the terms of the agreement, the parties will jointly evaluate and develop a pool of Emergent BioSolution's proprietary antigens as the basis of a multivalent subunit vaccine against Neisseria meningitidis infection.
Meningitec[TM] (Meningococcal Serogroup C Conjugate Vaccine) is a preservative free vaccine, which is delivered in ready-to-use pre-filled syringes for intramuscular injection for the prevention of invasive disease caused by Neisseria meningitidis serogroup C.
Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex.
Quagliarello V Dissemination of Neisseria meningitidis.
Mechanisms of meningeal invasion by septicemic extra cellular pathogens: the examples of Neisseria meningitidis, Streptococcus agalactiae and Escherichia coli (Join-Lambert, Carbonnelle, Chretien, Bourdoulous, Bonacorsi, Poyart and Nassif)
This reports provides an overview of the Neisseria Meningitidis Infections's therapeutic pipeline.
Neisseria meningitidis (meningococcus) is the causative 1 Vpathogen of invasive meningococcal disease (IMD), which includes a set of infectious syndromes, mainly meningitis or meningococcemia (septicemia) and, less commonly, pneumonia or other infections (1).
Neisseria meningitidis B has become the most prevalent of the serogroups that cause meningococcal disease in the US, accounting for 33 percent of all reported cases in 2013.
Microbiologists who are routinely exposed to isolates of Neisseria meningitidis.